IGNITE Program

Innovation Grants to Nurture Initial Translational Efforts (IGNITE)

A suite of early-stage therapy development funding programs called Innovation Grants to Nurture Initial Translational Efforts (IGNITE) is meant to serve a feeder program to the later-stage therapy development programs such as the Cooperate Research to Enable and Advance Translational Enterprises (CREATE) for Biologics and Blueprint Neurotherapeutics (BPN) Programs. 

IGNITE program applications will be reviewed within the NINDS Scientific Review Branch and not at the Center for Scientific Review (CSR).

Definitions for Key Terms

 

 

Timeline:

Grant Program

Entry Criteria

End Goal

Time

Budget Limit

PAR-15-070: Assay Development and Therapeutic Agent Identification and Characterization to Support Therapeutic Discovery (R21/R33)

Rationally selected assay(s) and therapeutic agents

Testing funnel to triage candidates, a battery of assays and starting agents that are well profiled

3 years total for both R21 and R33 stages, with no more than 2 years in either stage.

Total direct costs may not exceed $750,000 for the entire 3-year project period, with no more than $250,000 for the R21 phase, and with no more than $500,000 in direct costs in any single year.

PAR-15-071: Pharmacodynamics and In vivo Efficacy Studies for Small Molecules and Biologics/Biotechnology Products (R21/R33)

Evidence of validated/characterized animal model and PD measure, testing protocol and therapeutic agents

Well-characterized early-stage agents suitable for optimization

3 years total for both R21 and R33 stages, with no more than 2 years in either stage.

Total direct costs may not exceed $750,000 for the entire 3-year project period, with no more than $250,000 for the R21 phase, and with no more than $500,000 in direct costs in any single year.

 RFA-NS-16-013: Development and Validation of Model Systems and/or Pharmacodynamic Markers to Facilitate the Discovery of Neurotherapeutics (R21/R33)

Translational rationale for the proposed model system or pharmacodynamic marker and evidence of value for future drug discovery/development

Translationally relevant animal models, ex vivo systems, testing paradigms, and endpoints

3 years total for both R21 and R33 stages, with no more than 2 years in either stage.

Total direct costs may not exceed $250,000 per year, regardless of grant phase

Please be aware of these requirements:

Grant Program Entry Criteria End Goal Time Budget Limit

PAR-15-070: Assay Development and Therapeutic Agent Identification and Characterization to Support Therapeutic Discovery (R21/R33) Rationally selected assay(s) and therapeutic agents Testing funnel to triage candidates, a battery of assays and starting agents that are well profiled 3 years total for both R21 and R33 stages, with no more than 2 years in either stage. Total direct costs may not exceed $750,000 for the entire 3-year project period, with no more than $250,000 for the R21 phase, and with no more than $500,000 in direct costs in any single year.

PAR-15-071: Pharmacodynamics and In vivo Efficacy Studies for Small Molecules and Biologics/Biotechnology Products (R21/R33) Evidence of validated/characterized animal model and PD measure, testing protocol and therapeutic agents Well-characterized early-stage agents suitable for optimization 3 years total for both R21 and R33 stages, with no more than 2 years in either stage. Total direct costs may not exceed $750,000 for the entire 3-year project period, with no more than $250,000 for the R21 phase, and with no more than $500,000 in direct costs in any single year.

RFA-NS-16-013: Development and Validation of Model Systems and/or Pharmacodynamic Markers to Facilitate the Discovery of Neurotherapeutics (R21/R33) Translational rationale for the proposed model system or pharmacodynamic marker and evidence of value for future drug discovery/development Translationally relevant animal models, ex vivo systems, testing paradigms, and endpoints 3 years total for both R21 and R33 stages, with no more than 2 years in either stage. Total direct costs may not exceed $250,000 per year, regardless of grant phase.